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RESEARCH
Comparing hospital and telephone follow-up after
treatment for breast cancer: randomised equivalence trial
Kinta Beaver, professor of nursing,1 Debbie Tysver-Robinson, nurse consultant,2 Malcolm Campbell,
lecturer in statistics,1 Mary Twomey, research associate,1 Susan Williamson, research fellow,1 Andrew
Hindley, consultant clinical oncologist,3 Shabbir Susnerwala, consultant clinical oncologist,3 Graham Dunn,
professor of biomedical statistics,4 Karen Luker, professor of nursing1
ABSTRACT
Objective To compare traditional hospital follow-up with
telephone follow-up by specialist nurses after treatment
for breast cancer.
DesignA twocentre randomisedequivalence trial inwhich
women remained in the study for a mean of 24 months.
SettingOutpatient clinics in twoNHShospital trusts in the
north west of England
Participants 374 women treated for breast cancer who
were at low to moderate risk of recurrence.
Interventions Participants were randomised to traditional
hospital follow-up (consultation, clinical examination,
and mammography as per hospital policy) or telephone
follow-up by specialist nurses (consultation with
structured intervention and mammography according to
hospital policy).
Main outcome measures Psychological morbidity (state-
trait anxiety inventory, general health questionnaire
(GHQ-12)), participants’ needs for information,
participants’ satisfaction, clinical investigations ordered,
and time to detection of recurrent disease.
Results The 95% confidence interval for difference in
mean state-trait scores adjusted for treatment received
(−3.33 to 2.07) was within the predefined equivalence
region (−3.5 to 3.5). The women in the telephone group
were no more anxious as a result of foregoing clinic
examinationsand face-to-faceconsultationsand reported
higher levels of satisfaction than those attending hospital
clinics (intention to treat P<0.001). The numbers of clinical
investigations ordered did not differ between groups.
Recurrenceswere few (4.5%),withnodifferencesbetween
groups for time to detection (median 60.5 (range 37-131)
days in hospital group v 39.0 (10-152) days in telephone
group; P=0.228).
Conclusions Telephone follow-up was well received by
participants, with no physical or psychological
disadvantage. It is suitable for women at low to moderate
risk of recurrence and those with long travelling distances
or mobility problems and decreases the burden on busy
hospital clinics.
Trial registration National Cancer Research Institute
1477.
INTRODUCTION
In many countries clinical examination, consultation,
and routine mammography form the basis of routine
follow-up for women in remission from breast cancer,
with the primary objective of detecting recurrent
disease.1 This form of surveillance is as effective in
terms of overall survival and quality of life as more
intensive approaches,1 although whether routine fol-
low-up translates into improved survival is
questionable.2 Routine mammography alone might
confirm local recurrence in most treated women.3
Recurrences often present as interval events and are
not usually detected by clinical examination of patients
without symptoms.4-8National guidelines in theUnited
Kingdom state that intensive follow-up to detect
metastatic disease is not beneficial, although patients
should have continued access to specialist breast care
nurses for advice and support.9
Follow-up consultations could provide an opportu-
nity to meet information and psychosocial needs,
although thismight be challenging given that themean
duration for consultations is six minutes.10 Alternative
strategies, focusing less on survival and more on
patients’ satisfaction, have shown some benefit to
patients. General practitioners can be as effective at
providing follow-up care as hospital doctors,7 but there
is a clear need for appropriate training and resources to
transfer follow-up care from hospital to community.11
In the UK, follow-up continues primarily in hospital
clinics.
We based our study on previouswork in theUK and
Canada,12 13 which showed that women with breast
cancer need specific types of information and that new
follow-up strategies should be developed and
evaluated.10 With a proliferation of specialist nursing
posts worldwide, nurse led clinics are held for different
cancer groups. Breast care nurses are uniquely placed
to address the information and psychosocial needs of
affected women1415 and to provide follow-up services.
We built on existing evidence of the effectiveness of
telephone interventions for people with cancer16 to
deliver a structured intervention aimed primarily at
meeting needs for information. Communication by
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telephone is internationally relevant, particularly for
people in remote areas where travel to hospital is
inconvenient, time consuming, and costly.
METHODS
In this equivalence trial17 we examined whether,
despite foregoing face-to-face consultations and clin-
ical examinations, patients in the telephone arm of the
study had anxiety levels that were no different from
those of patients in the hospital arm.
Study sites and sample
All participants had been treated for breast cancer at a
large district general hospital or a specialist breast unit
in the north west of England. Inclusion criteria
included completion of primary treatment (surgery,
radiotherapy, chemotherapy), no evidence of recur-
rent disease, low to moderate risk of recurrence,18
access to a telephone, and adequate hearing. We
primarily determined the risk of recurrence using the
Nottingham prognostic index, considering tumour
size, spread to lymph nodes, and grade of cancer. We
also considered HER2 status as routine testing was
being introduced at the onset of the study. Consultant
surgeons and oncologists at the two study locations
agreed a written protocol for determination of risk
category. We included women with grade I and grade
II tumours if the tumour size was ≤50mmwith three or
fewer nodes affected. Women with grade III tumours
were included only if they were postmenopausal,
tumour size was ≤50 mm, no nodes were affected,
oestrogen receptor status was positive, and HER2
status was negative. We excluded inflammatory
carcinomas and sarcocarcinomas.With these inclusion
criteria no participant had a prognostic index >4.1,
indicating a low to moderate risk of recurrence.
We identified consecutive eligible patients in hospi-
tal clinics, discussed the study after appointments, and
subsequently contacted individuals for verbal and
written consent. Women who consented were rando-
mised to telephone or hospital follow-up. Researchers
contacted a central telephone randomisation service to
discover individual group allocation. Allocation
sequences were computer generated with randomised
permuted blocks with randomly varying block sizes,
stratified by study site and whether the participant was
on three, six, or 12 monthly follow-up. Allocation
sequences were concealed until interventions were
assigned. The analyst was blind to study group
allocation. Breast care nurses had no involvement in
randomisation or data collection procedures.
Procedures and intervention
Participants randomised to the hospital group con-
tinuedwithhospital follow-upas per hospital policy.At
the district general hospital participants were reviewed
every three months for two years, six monthly for two
years, then annually for a further year. At the specialist
breast unit they were reviewed annually for 10 years.
Preliminary work for the study had indicated that
hospital consultations were generally unstructured but
primarily consisted of a clinical examination, a check
on whether hormone treatment was being taken as
prescribed, and orderingmammograms if necessary.10
As per hospital policy, both study locations allocated
10 minutes for each individual hospital appointment.
Hospital consultations could be conducted by various
health professionals including consultant surgeons,
consultant oncologists, registrars, more junior doctors,
or specialist nurses. It wasmore usual at both locations,
however, for junior medical staff to conduct hospital
appointments.
Participants randomised to telephone follow-up
received telephone appointments from breast care
nurses at intervals consistent with hospital follow-up
policy. Appointment cards provided participants with
a date and time for their appointment; all telephone
appointments were registered on computerised hospi-
tal information systems so medical records staff could
access patients’ notes before telephone clinics. Each
individual telephone appointment was allocated
30minutes; 20minutes for conducting the consultation
and 10minutes to dictate the outcome of consultations.
Throughout the study the same specialist nurse
contacted each participant in the telephone group for
all appointments.
We developed a structured telephone intervention
fromprevious findingson informationneedsofwomen
with breast cancer,12 13 adapting a research instrument
for use as a clinical guide.19 Specific questions related to
changes in condition, new symptoms, and information
Excluded (n=2169):
  Did not meet inclusion criteria (n=1646)
  Refused consent (n=255)
  Missed by researchers (n=172)
  Patient did not attend (n=95) 
Medical notes assessed for eligibility at 968 clinic sessions (n=24 362)
Patients identified as routine breast cancer follow-up (n=2542)
Randomised (n=374)
Hospital follow-up (n=183):
  Received allocated intervention (n=175)
  Did not receive allocated intervention (patient
    request to change group n=8)
Telephone follow-up (n=191):
  Received allocated intervention (n=173)
  Did not receive allocated intervention (n=18):
    Patient request to change group (n=15)
    Health professional request for change of
      group (n=2)
    Administrative error (n=1)
Lost to follow-up (n=22):
  Recurrence of breast cancer (n=11)
  Patient request to withdraw (n=3)
  Ovarian cancer (n=2)
  Cervical cancer (n=2)
  Other cancers (n=2)
  Death unrelated to breast cancer (n=2)
Returned questionnaires:
  At start of trial (n=175, 91.6%)
  At middle of trial (n=138, 72.3%)
  At end of trial (154, 80.6%)
Returned questionnaires:
  At start of trial (n=171, 93.4%)
  At middle of trial (n=121, 66.1%)
  At end of trial (n=145, 79.2%)
Lost to follow-up (n=11):
  Recurrence of breast cancer (n=6)
  Patient request to withdraw (n=2)
  Ovarian cancer (n=2)
  Death unrelated to breast cancer (n=1)
Fig 1 | Flow of participants through trial
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requirements about spread of disease, treatment and
side effects, genetic risk, sexual attractiveness, self care
(diet, support groups, finances), and family concerns.
Standard protocols related to routine mammography
were unaltered.
Breast care nurses underwent four half day training
sessions on the administration of the telephone inter-
vention with subsequent feedback and debriefing
sessions throughout the study period. Seven nurses
received training, although one nurse at the district
general hospital and three nurses at the specialist breast
unit conducted most telephone appointments. To
monitor the integrity of the intervention, all telephone
consultations were recorded with consent of the
women.
Outcome measures
Outcomes includedpsychologicalmorbidity, informa-
tion needs, participants’ satisfaction, clinical investiga-
tions ordered, and time to detection of recurrent
disease. We designed and piloted questionnaires on
information needs and participants’ satisfaction.19 We
measured psychological morbidity using two
instruments. The Spielberger state-trait anxiety inven-
tory (STAI) is a 40 item self report instrument
distinguishing between short term anxiety (state)
initiated by current life events (STAI Y1, 20 items)
and anxiety as a personality trait (STAI Y2, 20 items,
administered only initially).20 The general health
questionnaire (GHQ-12) is a 12 item, well validated
instrument focusing on broad aspects of psychological
morbidity and designed to be self administered.21 We
also examined cost effectiveness andwill report on this
elsewhere.
We collected clinical data prospectively. A record of
visit form recorded actions resulting from consulta-
tions and indicators of recurrence in the hospital arm.
The recorded telephone appointments provided
equivalent data. We used two key index dates to
establish time to diagnosis of recurrence: date of first
presentation of symptoms (or indicator of recurrence)
and date recurrence was confirmed to participants.
Time to diagnosis of recurrence was taken as the
difference between the two index dates. As the sample
included only those at low to moderate risk of
recurrence we expected only a few recurrences during
the study period. We could not draw firm conclusions
relating to detection of recurrence but compared
recurrences between groups. At the end of the study
we retrospectively examined all participants’ case
notes to check accuracy of data on recurrence.
For practical reasons we could not administer
outcome questionnaires before randomisation. We
sent initial questionnaires to patients immediately after
randomisation, a minimum of three months before
their next appointment. Questionnaires were also
administered at the middle and end of the trial,
established on an individual basis, depending on how
long participants remained in the study. These were
posted to participants immediately after telephone or
hospital appointments tomaximise participants’ recall.
Members of the research team posted all outcome
measures with pre-paid return postal service. Health
professionals who conducted follow-up consultations
as part of this study had no involvement in the
administration of outcome measures.
Statistical analysis
Contrary to a standard comparative trial, an equiva-
lence trial has analternativehypothesis of nodifference
between treatments or services.22 We calculated our
sample size on the basis of findings from pilot work
related to state-trait scores.19 The pilot study compared
scores for the intervention (telephone follow-up by
specialist nurses) and control group (hospital follow-
up); we used differences in mean scores between
groups to define an equivalence region for the current
study. Our study was powered on the basis of a 95%
equivalence region of −3.5 to 3.5 for the difference in
mean state-trait scores between groups at the end of the
trial, 3.5 being 10% of the expected control mean, with
an expected SD of 10.0. The required sample size was
129 per group.23 Assuming 20% drop out by the end of
the trial, we aimed to achieve 162 per group.
Table 1 | Sociodemographic characteristics of women with breast cancer according to hospital
or telephone follow-up. Figures are numbers (percentages) of women unless stated otherwise
Hospital (n=183) Telephone (n=191) Total (n=374)
Age at recruitment (years):
Mean (SD) 64.0 (11.1) 63.9 (10.1) 64.0 (10.6)
Median (range) 63.0 (36-87) 64.0 (42-93) 64.0 (36-93)
<45 9 (5) 4 (2) 13 (4)
45-54 26 (14) 32 (17) 58 (16)
55-64 67 (37) 60 (31) 127 (34)
65-74 46 (25) 60 (31) 106 (28)
≥75 35 (19) 35 (18) 70 (19)
Marital status:
Married/cohabiting 117 (64) 123 (64) 240 (64)
Divorced/separated 15 (8) 21 (11) 36 (10)
Widowed 38 (21) 39 (20) 77 (21)
Never married 13 (7) 8 (4) 21 (6)
Employment status at recruitment*:
Employed full time 28 (16) 29 (15) 57 (15)
Employed part time 29 (16) 29 (15) 58 (16)
Retired 115 (64) 121 (64) 236 (64)
Unemployed 5 (3) 2 (1) 7 (2)
Long term sick 3 (2) 7 (4) 10 (3)
Other 1 (1) 2 (1) 3 (1)
Social class (based on current/previous occupation)*:
Managers and senior officials 13 (8) 19 (12) 32 (10)
Professional 15 (10) 18 (11) 33 (10)
Associate professionals/technical 20 (13) 20 (12) 40 (13)
Administrative/ secretarial 48 (31) 35 (22) 83 (26)
Skilled trades 11 (7) 7 (4) 18 (6)
Personal service 9 (6) 23 (14) 32 (10)
Sales/customer services 12 (8) 13 (8) 25 (8)
Process, plant, and machine
operatives
4 (3) 2 (1) 6 (2)
Elementary occupations 25 (16) 25 (15) 50 (16)
*Small numbers of missing values.
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Weentered and analysed data with SPSS, release 15.
Scoring of standard psychological measures was
conducted as recommended in scoring manuals.20 21
State-trait scores range from 20 to 80 and GHQ-12
scores from 0 to 12 (scores ≥4 indicate caseness), with
higher scoresonbothmeasures indicatinghigher levels
of psychological morbidity. We compared the out-
come used to assess equivalence (the state-trait score)
between groups in two ways, starting with an intention
to treat analysis. When there are protocol violations,
the intention to treat effect will be biased in favour of
equivalence.24 We used a two stage approach to
estimate the effects of treatment received adjusted for
the hidden effects of non-compliance—an adjusted
treatment received analysis.25 We used regression,
firstly, to predict treatment received from randomised
group and pre-randomisation covariates and, sec-
ondly, to predict the outcome variable from treatment
received, the residuals from the first stage and the same
covariates.26 This is equivalent to a two stage least
squares approach.27 Regression models for the first
stage of analyses adjusted for treatment received were
fitted as general linear models. Models for intention to
treat analyses and the second stage of analyses adjusted
for treatment receivedacross the three timepointswere
fittedwith linearmixedmodels,with either randomisa-
tion group or treatment received, respectively, strati-
fication variables (site and follow-up status), and time
point as fixed factors and patient as a random factor.28
Such models allow for non-independent observations
and use all outcome data (we dropped the small
number of patients with no state-trait data from the
analysis), assuming missing data to be missing at
random.29
We initially fitted saturated models but as no
interactions were significant we have presented results
for main effects models. Standard deviations of
residuals were similar over combinations of fixed
factors except where subgroup sizes were small. For
assessing equivalence, we compared state-trait scores
between study groups using a two sided 95% con-
fidence interval for the difference between estimated
marginal means. Results are also given for similar
intention to treat and adjusted treatment received
analyses at specific time points, fitted as general linear
models. We compared other measures between
randomised groups under intention to treat analysis
using χ2 test and Fisher’s exact test, including its
extension to tables larger than2×2 (nominalmeasures),
the χ2 test for trend (ordinal), theMann-WhitneyU test
(skewed), and the unpaired t test (interval). Outcomes
were compared between time points using the McNe-
mar test (dichotomous), the Wilcoxon matched pairs
test (skewed), and the paired t test (interval). Logistic
regression was used to assess association between
sociodemographic or clinical characteristics and parti-
cipation at the end of the trial.
Monitoring
A trial management group, including clinicians,
researchers, and lay representatives, met on several
occasions to discuss anddebate key aspects of the study
and to monitor study progress.
RESULTS
Recruitment took place between March 2003 and
August 2005. Data collection continued until October
2006; patients remained in the study for a mean of
24 months (range 2-43 months). Many patients
approachedwhomet the inclusion criteriawerewilling
to participate (374/629, 60%, fig 1); 215 patients who
did not take part provided sociodemographic and
treatment information and a reason for refusal,
including a preference for face-to-face consultations
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Fig 2 | Mean differences with 95% confidence intervals for
telephone group minus hospital group for state-trait anxiety
inventory according to method of analysis
Table 2 | Details of disease and treatment in women with breast cancer according to hospital or
telephone follow-up. Figures are numbers (percentages) of women
Hospital (n=183) Telephone (n=191) Total (n=374)
How breast cancer was detected:
Breast screening programme 78 (43) 83 (44) 161 (43)
Patient presented with symptoms 99 (54) 107 (56) 206 (55)
Other 6 (3) 1 (0.5) 7 (2)
Type of surgery:
Mastectomy 65 (36) 78 (41) 143 (38)
Lumpectomy/wide local excision 118 (65) 113 (59) 231 (62)
Received radiotherapy* 109 (60) 106 (56) 215 (58)
Received chemotherapy* 18 (10) 16 (8) 34 (9)
Time from diagnosis† (months):
Median (range) 20.0 (1-107) 18.0 (1.25-92) 20.0 (1-107)
≤12 56 (31) 70 (37) 126 (34)
13-24 57 (31) 51 (27) 108 (29)
25-36 26 (14) 24 (13) 50 (13)
>36 43 (24) 46 (24) 89 (24)
Time from first visit after treatment† (months):
Median (range) 17.0 (0.5-106) 15.0 (0.5-91) 15.0 (0.5-106)
≤12 75 (41) 87 (46) 162 (43)
13-24 45 (25) 39 (20) 84 (23)
25-36 36 (20) 27 (14) 63 (17)
>36 26 (14) 38 (20) 64 (17)
Follow-up status:
3 monthly 61 (33) 67 (35) 128 (34)
6 monthly 71 (39) 73 (38) 144 (39)
12 monthly 51 (28) 51 (27) 102 (27)
*Small numbers of missing values.
†One value missing because participant was initially diagnosed and treated in different area; no accurate data
available.
RESEARCH
page 4 of 9 BMJ | ONLINE FIRST | bmj.com
 on 28 January 2009 bmj.comDownloaded from 
and a preference for clinical examination. Some family
members did not want their relative to take part as they
thought they would be excluded from consultations if
the appointment was conducted by telephone. Partici-
pants were randomised to hospital (183, 49%) or
telephone (191, 51%) follow-up. Initially, sociodemo-
graphic and clinical characteristics for those rando-
mised were broadly similar in the two study groups
(tables 1 and 2). The sample was representative in
terms of age, with more participants in the 55-64 year
age group than in the other age group categories
(table 1), in line with data from the UK Office for
National Statistics. 30 Participants were a median of
20 months from diagnosis, although most (63%) were
24 months or less from diagnosis (table 2). Over the
courseof the studyover500 telephoneand500hospital
appointmentswere conductedwithparticipants. Those
who refused to take part differed from participants in
study site, social class, and follow-up status. Patients at
the specialist breast unit (71%)weremore likely towant
to participate than those at the district general hospital
(61%, χ2=5.01, df=1, P=0.025), participants fromhigher
social classes (professional occupations) were more
likely to want to participate than those from lower
social classes (χ2=15.77, df=8, P=0.046), and
participants with three to 12 months between visits
(67.7%, 70.6%) were more likely to participate than
those on six monthly follow-up (58.1%, χ2=7.66, df=2,
P=0.022). Time from diagnosis did not differ signifi-
cantly for those who did or did not take part (t=−0.26,
P=0.80); those who refused to take part were a median
of 21 months from diagnosis.
There were 26 protocol violations between baseline
and the end of the trial (7% of those randomised, fig 1).
Sociodemographic and clinical data were collected for
all randomised participants. The proportion returning
questionnaire data was lowest in themiddle of the trial:
for some participants we could administer the ques-
tionnaires only at the start and end of the trial because
of lengthy gaps between appointments. Eight patients
from the specialist breast unit and 17 from the district
general hospital did not return questionnaires at any
timepoint.Among the 349otherpatients, participation
at the end of the trial was not associated with any of the
variables in tables 1 and 2 at 10% significance using
logistic regression models, apart from time from
diagnosis (likelihood ratio χ2=3.28, df=1, P=0.070)
and time from first visit after treatment (χ2=2.90, df=1,
P=0.089). Those participating at the end of the trial had
a shorter time from diagnosis at the start of the trial
(median 18 months) than those who had dropped out
after participating at least once (median 25.5 months,
Mann-Whitney U=5902.5, P=0.019), and a shorter
time frompost-treatment visit at the start of the trial (15
v 25 months, U=6046.0, P=0.033).
Psychological morbidity
Differencesbetweengroups in state-trait scorewerenot
significant at the start, middle, or end of the trial under
intention to treat or adjusted treatment received
analyses, although means were consistently lower for
the telephone group (table 3). Mean score did not
significantly improve during the trial, the mean
reduction from the start to the end of the trial being
0.33.
Figure 2 shows 95% confidence intervals for the
differences betweenmean values (hospital v telephone)
of state-trait scores for intention to treat and adjusted
treatment received analyses with linear mixedmodels.
Positive differences in means indicate more anxiety in
the telephone group, while negative differences
indicate more anxiety in the hospital group. Both
confidence intervals were within the prestated equiva-
lence region of −3.5 to 3.5, indicating equivalence. 22
We compared groups for other variables under
intention to treat analysis. GHQ-12 scores were highly
skewed,with over 49%of scoreswithin a group being 0
at each time point. Differences between randomised
groups at the start, middle, or end of the trial were not
significant, nor were differences between time points.
Although the percentage of cases (scores ≥4) was
consistently higher in the hospital group at the start,
middle, and end of the trial, differences between the
groups at each time point were not significant. Initially,
71/328 (22%) were GHQ-12 cases compared with 47/
Table 3 | State-trait anxiety inventory (STAI) findings by study group adjusted for site and
follow-up status (analysis by intention to treat or adjusted for treatment received)
Group
No of
women
Estimated marginal mean
(95% CI) F
df
, P value
95% CI for
difference*
Intention to treat
Start of trial (STAI Y1):
Hospital 158 36.45 (34.42 to 38.49)
0.051,320, 0.821 −2.88 to 2.28
Telephone 167 36.16 (34.12 to 38.20)
Start of trial (STAI Y2):
Hospital 156 39.20 (37.19 to 41.21)
1.841,313, 0.176 −4.32 to 0.79
Telephone 162 37.43 (35.41 to 39.46)
Middle of trial:
Hospital 108 34.95 (32.20 to 37.70)
1.111,228, 0.293 −4.64 to 1.41
Telephone 125 33.33 (30.59 to 36.08)
End of trial:
Hospital 132 35.65 (33.36 to 37.95)
0.261,271, 0.608 −3.61 to 2.18
Telephone 144 34.91 (32.65 to 37.16)
Start, middle, and end of trial†:
Hospital 398 36.13 (34.33 to 37.93)
0.241,326.2, 0.623 −2.82 to 1.69
Telephone 436 35.57 (33.78 to 37.36)
Adjusted for treatment received
Middle of trial:
Hospital 111 35.07 (32.18 to 37.96)
1.131,227, 0.290 −5.42 to 1.63
Telephone 122 33.18 (30.27 to 36.09)
End of trial:
Hospital 136 35.67 (33.20 to 38.14)
0.221,270, 0.637 −4.27 to 2.62
Telephone 140 34.85 (32.37 to 37.34)
Start, middle, and end of trial†:
Hospital 413 36.15 (34.23 to 38.08)
0.211,325.8, 0.648 −3.33 to 2.07
Telephone 421 35.52 (33.56 to 37.49)
*Telephone group minus hospital group (negative differences imply less anxiety in telephone group).
†Linear mixed model. Mean difference from start to middle of trial −0.66, paired t=−1.04, df=225, P=0.301, 95%
CI −1.90 to 0.59. Mean difference from start to end of trial −0.24, paired t=−0.36, df=266, P=0.718, 95% CI
−1.52 to 1.05.
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281 (17%)at theendof the trial.Change for the266with
data at both time points was not significant.
Information needs
Participants clearly indicated their specific information
needs (table 4). Initially, the highest need related to
information about genetic risk, the lowest for informa-
tion on sexual attractiveness. Within both randomised
groups, information needs reduced over time for all
items. Therewas little difference between the groups in
information needs, apart from information on sexual
attractiveness in the middle of the trial. The need for
information on genetic risk remained the highest at the
end of the trial, with 92 of the 296 respondents to the
question (31%) still requiring information.
Participants’ satisfaction
There were no significant differences between rando-
mised groups initially regarding satisfaction with
information received (table 5). The telephone group
showed significantly more satisfaction at the middle
andendof the trial (P<0.001).Participantswereasked if
they had thought that the appointment had been
helpful in dealing with their concerns. There was no
difference between groups initially but at the middle
and end of the trial, responses were significantly more
positive in the telephone group, with a higher
percentage reporting “very helpful” and few with
negative responses (table 6).
Table 7 shows the numbers of contacts with health
professionals or administrative staff between appoint-
ments for both groups; contacts were relatively few but
were primarily with breast care nurses, general
practitioners, and lymphoedema nurses. There were
no significant differences between groups in terms of
contact at any time point. Women who had contact
with their general practitioners, however, tended to
have been diagnosed more recently (median
10 months compared with 20 months for those with
no reported contact, Mann-Whitney U=2044.0,
P=0.004). Women who had contact with breast care
nurses between appointments also tended to have been
diagnosed more recently (median 6.5 months com-
pared with 20 months for those with no reported
contact, U=1488.5, P=0.001). Contact with lympho-
edema nurses was not associated with time from
diagnosis (U=1895.5, P=0.244). There were few con-
tacts with hospital doctors and administrative staff
between visits, and numbers were too small for
additional analysis.
Clinical investigations ordered
There were no differences between groups in whether
clinical investigationswereordered forparticipants as a
result of appointments at the start (hospital 29% v
telephone 24%, χ2=1.10, df=1, P=0.294),middle (36% v
34%, χ2=0.08, df=1, P=0.772), or end of the trial (40% v
43%, χ2=0.32, df=1, P=0.574). In most cases, investiga-
tions comprised routine mammograms. Other inves-
tigations mentioned by both groups at all stages of the
study included 18 non-routine mammograms, 13
blood tests, nine chest x ray investigations, nine bone
scans, six fine needle aspirations/biopsies, and one
magnetic resonance imaging scan.
Time to detection of recurrence
Only 17 participants (5%) had a confirmed recurrence
of cancer during the trial: six in the hospital group and
11 in the telephone group (table 8). The difference
between randomised groups was not significant
(χ2=1.33, df=1, P=0.250. Themedian time to confirma-
tion was 60.5 days (range 37-131 days) in the hospital
group and 39.0 days (10-152 days) in the telephone
group (Mann-Whitney U=21.0, P=0.228, for differ-
ence).
DISCUSSION
Positive benefit
Telephone follow-up by specialist breast care nurses
haspositivebenefits forwomenwithbreast cancer.Our
studywas specifically designed tomeet the information
needs of patients. It was encouraging that nearly 60%
agreed to participate, given that patients find hospital
visits reassuring10 and theywereasked to foregoclinical
examinations. Routine mammograms took place
irrespective of group allocation and this might have
had an impact on patients’ preferences for participa-
tion, particularly for those patients with lesions
detected at screening who had no symptoms on initial
presentation.
Table 4 | Information needs at start, middle, and end of trial
by randomised group. Figures are numbers (percentages) of
women
Time in trial Hospital Telephone
Spread of disease:
Start 62/170 (37) 70/175 (40)
Middle 19/121 (16) 24/136 (21)
End 25/145 (17) 32/153 (21)
Treatment and side effects:
Start 64/168 (38) 71/174 (41)
Middle 22/121 (18) 22/137 (16)
End 24/144 (17) 30/153 (18)
Genetic risk:
Start 74/168 (44) 76/174 (44)
Middle 34/121 (28) 43/137 (31)
End 43/144 (30) 49/152 (32)
Sexual attractiveness:
Start 30/170 (18) 37/174 (21)
Middle 18/121 (15) 9/137 (7)
End 15/144 (10) 20/153 (13)
Self care:
Start 55/170 (32) 58/175 (33)
Middle 18/121 (22) 26/136 (19)
End 25/144 (17) 23/153 (15)
Family concerns:
Start 48/170 (28) 40/175 (23)
Middle 21/121 (17) 19/138 (14)
End 20/145 (14) 16/153 (11)
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Our study was not about finding the most useful or
sensitive tests and investigations for detecting recur-
rence. We focused on the consultation between
participants and clinicians, aiming to provide partici-
pants with the information and support they needed,
when they needed it, to cope with the diagnosis of
cancer. The telephone intervention provided a service
to participants thatmet their needs,with no evidence of
physical or psychological disadvantage. This trial was
primarily designed to evaluate whether there was
equivalence, in terms of psychological morbidity,
between hospital and telephone follow-up, and this
was shown under the more conservative approach
adjusted for treatment received.
Scores on the state-trait anxiety inventory did not
significantly improve in either group during the trial,
and this might indicate that, although this measure has
been used successfully with patients with breast cancer
in previous studies, it was not sufficiently sensitive to
capture changesover time in this study.Findings for the
anxiety inventory and GHQ-12 indicated that there
were no differences between scores for study groups at
any point in the trial. Participants who received
telephone follow-up were not more anxious as a result
of foregoinghospital contact andclinical examinations.
Those in the telephone group reported greater
satisfactionwith the information received and reported
appointments as more helpful in meeting their needs.
The telephone intervention was specifically designed
to provide information and hence met its objectives.
The percentage of participants requiring information
on specific needs at the endof the trial ranged from10%
to 32%.Considering that participantswere amedian of
20 months from diagnosis at the point of recruitment
and remained in the study for a mean of 24 months,
Table 6 | Helpfulness in dealing with concerns at appointment
by randomised group (intention to treat analysis). Figures are
numbers (percentages) of women
Level of
satisfaction Hospital Telephone χ2
trend
, P value
Start of trial
Very helpful 44 (48) 44 (52)
0.69, 0.405
Helpful 36 (39) 31 (37)
Not very helpful 10 (11) 9 (11)
Very unhelpful 2 (2) 0 (0)
Overall 92 (100) 84 (100) −
Middle of trial
Very helpful 28 (44) 80 (88)
28.27, <0.001
Helpful 26 (41) 9 (10)
Not very helpful 9 (14) 1 (1)
Very unhelpful 1 (2) 1 (1)
Overall 64 (100) 91 (100) −
End of trial
Very helpful 42 (63) 84 (84)
10.35, 0.001
Helpful 15 (22) 13 (13)
Not very helpful 10 (15) 2 (2)
Very unhelpful 0 (0) 1 (1)
Overall 67 (100) 100 (100) −
Table 5 | Satisfaction with information received by randomised group (intention to treat analysis). Figures are numbers (percentages) of women
Level of satisfaction Hospital Telephone
Between groups comparison P value
All categories* First 4 categories
Start of trial
Very satisfied 79 (46) 78 (45)
0.671
χ2trend=0.31, 0.576
Satisfied 67 (39) 71 (41)
Not very satisfied 4 (2) 8 (5)
Very unsatisfied 1 (1) 0 (0.0)
Did not receive information 10 (6) 6 (4) −
Did not need information 10 (6) 10 (6) −
Overall 171 (100) 173 (100) −
Middle of trial
Very satisfied 57 (49) 110 (80)
<0.001
χ2trend=19.07, <0.001
Satisfied 41 (35) 22 (16)
Not very satisfied 7 (8) 3 (2)
Very unsatisfied 3 (3) 1 (1)
Did not receive information 4 (3) 0 (0) −
Did not need information 4 (3) 1 (1) −
Overall 116 (100) 137 (100) −
End of trial
Very satisfied 78 (55) 121 (80)
<0.001
χ2trend=14.33, <0.001
Satisfied 47 (33) 25 (16)
Not very satisfied 8 (6) 3 (2)
Very unsatisfied 1 (1) 1 (1)
Did not receive information 7 (5) 0 (0) −
Did not need information 1 (1) 2 (1) −
Overall 142 (100) 152 (100) −
*Fisher’s exact test.
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 7 of 9
 on 28 January 2009 bmj.comDownloaded from 
many patients retained a need for information long
after completion of treatment. Breast care nurses in the
telephone arm of the study received training in
administering the structured intervention, designed to
meet information needs. Provision of training in
meeting information needs for all heath professionals
involved in providing follow-up care for women
treated for breast cancer could be beneficial.
There were no differences in terms of investigations
ordered between groups. A lack of visual cues did not
result in more tests being ordered. These findings,
however, arebasedonparticipants’ retrospective recall
of investigations ordered; response might have been
subject to inaccuracies. As part of this study we
collectedmore detailed data on resource use to inform
an economic evaluation that will present a more
detailed and accurate picture of tests and investigation.
Participants in the telephonegroupwerenomore likely
to consult with other health professionals between
visits than those in the hospital group and so were not
using additional healthcare resources. Women who
initiated contact with breast care nurses and general
practitioners between appointments tended to be less
than a year from diagnosis; negotiating frequency of
appointments with patients might be appropriate to
meet differing needs at different time points.
Strengths and limitations
The study provides limited information about time to
detection of recurrent disease as the participants had a
low tomoderate riskof recurrence;only17 recurrences
were detected. These were mostly interval events; no
recurrences were detected in patients without symp-
toms at routine appointments. There were no differ-
ences in time to detection of recurrence between the
groups. Despite appointments taking place over the
telephone, there were no undue delays in identifying
potential clinical problems and instigating appropriate
referral processes. Given these positive findings, a
similar approach could be considered for patients in all
risk categories as follow-up does not usually have a
different format for high risk groups. At this stage,
however, our findings can be applied with confidence
only to women at low risk of recurrence; we did not
have a large enough sample to provide robust data on
time to detection of recurrence, and larger studies
would be needed across risk groups to determine if
telephone follow-up could be effective for women at
high risk of recurrence.More work would also identify
the specific needs of patients at high risk of recurrence
with subsequent adaptation of the intervention instru-
ment.
The telephone intervention presented a structured
approach to follow-up, which could have several
advantages. Information could be repeated at each
appointment; patients might not recall information
previously given or might find repetitive information
reassuring. The structure allows patients to choose
what information is important to them and when it is
important. Administration of the telephone inter-
vention requires training as high levels of skill and
Table 7 | Reported number of contacts with health
professionals between appointments by randomisation
group
Hospital Telephone
Breast care nurses
Baseline 14 26
Middle of trial 13 18
End of trial 15 14
General practitioners
Baseline 14 13
Middle of trial 12 9
End of trial 14 13
Lymphoedema nurses
Baseline 10 13
Middle of trial 10 7
End of trial 14 19
Hospital doctor
Baseline 4 3
Middle of trial 3 6
End of trial 6 3
Hospital administrative/secretarial staff
Baseline 4 7
Middle of trial 3 4
End of trial 5 4
Community nurses
Baseline 3 1
Middle of trial 0 1
End of trial 3 1
Table 8 | Characteristics of patients with confirmed recurrence of cancer by randomised group
(intention to treat analysis)
Hospital Telephone P value*
Study site:
District general hospital 5 10
0.999
Specialist breast unit 1 1
Type of recurrence:
Local 4 4
0.335
Distant metastases 2 7
Patient died (related to breast cancer):
Yes 2 6
0.620
No 4 5
Presentation:
Contacted general practitioner 3 6
0.891
Phoned breast care nurse 1 1
Presented symptoms to breast care nurse
during pre-arranged appointment
0 2
Routine mammogram 2 2
Routine/interval visit:
Routine appointment, patient
symptomatic
0 2
0.787Interval visit, patient with symptoms 4 7
Interval presentation, routine
mammogram
2 2
Totals 6 11 −
*Fisher’s exact test.
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knowledge are essential, and breast care nurses are
ideally anduniquelyplaced for this role. This studywas
conducted within the confines of clinical reality, given
all the usual challenges of staff shortages and sickness;
no additional nursing services were provided. Specia-
list nurses would probably not have the capacity to
provide telephone follow-up to all women treated for
breast cancer, even if eligibility was limited to those at
low risk of recurrence. Telephone follow-up might
reduce the burden on busy hospital clinics, but other
approaches might also be effective. Alternating tele-
phone and hospital follow-up, according to patients’
preferences, could be a suitable approach, while
hospital follow-up might continue to be preferred by
those who do not feel comfortable discussing their
concerns over the telephone.
Telephone follow-up is convenient, especially in
rural areas where patients might have to travel long
distances for hospital appointments and for those with
limited mobility. Patients might also feel more
comfortable in their own homes, where they cannot
see the “busyness” of hospital clinics, and might take
the opportunity to be more proactive in seeking
answers to their questions. Telephone follow-up
might have broader applicability to other groups of
patients. There are nurse specialists for many diseases
and their skills could be harnessed to provide a quality
service while reducing the burden on busy hospital
clinics.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
UK national guidelines recommend that routine long term follow-up after treatment for breast
cancer is not effective at prolonging survival
Brief consultations aimed at detection of recurrence do not provide opportunities for
discussion of information and psychosocial needs
WHAT THIS STUDY ADDS
Participants in a telephone follow-up group were no more anxious as a result of foregoing
clinical examinations and face-to-face contact
Telephone follow-up was associated with high levels of satisfaction in patients
Telephone follow-up might decrease the burden on busy hospital clinics
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